Molecular Partners AG
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com
According to the Complaint, the Company made false and misleading statements to the market. Molecular Partners’ ensovibep was not as effective at treating COVID-19 as the Company had stated. The FDA was likely to require an additional Phase 3 study before granting the drug a EUA. The decreasing rate of COVID-19 globally diminished the likelihood of the FDA granting a EUA to the Company. The Company’s product candidate MP0310 was of less interest to Amgen than it led the market to believe. There was a significant chance that Amgen would return global rights to the product candidate back to the Company. Based on these facts, the Company’s public statements were false and materially misleading throughout the IPO and class period. When the market learned the truth about Molecular Partners, investors suffered damages.
